OMER vs AVLN
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
OMER · Omeros$16.92 ▼ 0.88%
AVLN · Avalyn Pharma$29.15 ▲ 9.30%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- OMER +15.9%
- AVLN -1.2%
Head to head
| Metric | OMER | AVLN |
|---|---|---|
| Price | $16.92 | $29.15 |
| Change today | ▼ 0.88% | ▲ 9.30% |
| Market cap | $1.22B | $1.29B |
| Return, 3 months | +24.2% | -15.7% |
| Return, year to date | -1.5% | – |
| Return, 1 year | +156.8% | – |
| P/E (TTM) | 9.8 | -12.5 |
| P/B | -23.9 | 3.2 |
| P/E percentile vs own 5y | 93rd | 89th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | +152.0% | -43.3% |
| Gross margin | 97.2% | – |
| Operating margin | -189.5% | – |
| Net margin | 324.9% | – |
| Return on equity | – | -25.9% |
| Analyst target vs. price | +62.5% | +93.2% |
| Analyst buy share | 67% | 100% |
| RSI (14) | 44 | 60 |
| 30-day volatility | 63.4% | 63.5% |
| Max drawdown, 1 year | -49.5% | -40.6% |
| Trend read | Leaning bearish | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- AVLN is the largest of the group by market value.
- AVLN carries the lowest trailing P/E.
- OMER has been the calmest stock over the last 30 days.